Tag: Health Care

Alpha Cognition
Global

Alpha Cognition Announces Appointment of VP Finance and Accounting

October 21, 2024 – VANCOUVER, British Columbia – Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF)(“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO). “I am excited to join Alpha Cognition at such a critical juncture” Post … Continue reading Alpha Cognition Announces Appointment of VP Finance and Accounting

Impact Newswire
Vianautis
Untied Kingdom

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who has been stepping down from her role. Dr Adi Hoess brings a wealth of experience to ViaNautis, having previously served as CEO of Nasdaq-listed German … Continue reading ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

Impact Newswire
CVS Health
United States

CVS Health Appoints David Joyner President and Chief Executive Officer

October 18, 2024 Roger Farah Named Executive Chairman of the Board Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10 WOONSOCKET, RI (October 18, 2024) – CVS Health (NYSE: CVS) today announced that David Joyner was appointed President and Chief Executive Officer, effective October 17, replacing Karen Lynch, who stepped … Continue reading CVS Health Appoints David Joyner President and Chief Executive Officer

Impact Newswire
Seaport Therapeutics
United States

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 … Continue reading Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Impact Newswire
Sanofi
Europe

Sanofi and Orano join forces to develop next-generationradioligand medicines

Press Release – Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will … Continue reading Sanofi and Orano join forces to develop next-generationradioligand medicines

Impact Newswire